Perrigo Company plc Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax of $0 for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax · last filed 2026-08-05
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-06-27 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-03-28 was $500.00K, a 90.20% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-12-31 was $1.80M, a 71.43% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-09-27 was $3.70M, a 57.95% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2025 was $15.10M, a 52.06% decline from fiscal 2024.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2024 was $31.50M, a 33.47% increase from fiscal 2023.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2023 was $23.60M, a 1715.38% increase from fiscal 2022.
- Perrigo Company plc other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2022 was $1.30M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-27 | $0.00 10-Q · filed 2026-08-05 | $500.00K 10-Q · filed 2026-08-05 | $2.30M derived: sum of 3 quarters · filed 2026-08-05 | $6.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $500.00K 10-Q · filed 2026-05-06 | $2.30M derived: sum of 2 quarters · filed 2026-05-06 | $6.00M derived: sum of 3 quarters · filed 2026-05-06 | $10.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.50M derived: sum of 2 quarters · filed 2026-02-26 | $10.10M derived: sum of 3 quarters · filed 2026-08-05 | $15.10M 10-K · filed 2026-02-26 |
| 2025-09-27 | $3.70M 10-Q · filed 2025-11-05 | $8.30M derived: sum of 2 quarters · filed 2026-08-05 | $13.30M 10-Q · filed 2025-11-05 | $19.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $4.60M 10-Q · filed 2026-08-05 | $9.60M 10-Q · filed 2026-08-05 | $16.00M derived: sum of 3 quarters · filed 2026-08-05 | $24.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $5.10M 10-Q · filed 2026-05-06 | $11.40M derived: sum of 2 quarters · filed 2026-05-06 | $20.20M derived: sum of 3 quarters · filed 2026-05-06 | $28.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.10M derived: sum of 2 quarters · filed 2026-02-26 | $23.80M derived: sum of 3 quarters · filed 2026-02-26 | $31.50M 10-K · filed 2026-02-26 |
| 2024-09-28 | $8.80M 10-Q · filed 2025-11-05 | $17.50M derived: sum of 2 quarters · filed 2025-11-05 | $25.20M 10-Q · filed 2025-11-05 | $32.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | $8.70M 10-Q · filed 2025-08-06 | $16.30M 10-Q · filed 2025-08-06 | $23.60M derived: sum of 3 quarters · filed 2026-02-26 | $30.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $7.90M 10-Q · filed 2025-05-07 | $14.90M derived: sum of 2 quarters · filed 2026-02-26 | $21.30M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.40M derived: sum of 2 quarters · filed 2026-02-26 | $23.60M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $6.40M 10-Q · filed 2024-11-06 | $16.60M 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | $1.30M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |